Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era.

"appendix a supplementary data the following are the supplementary data to this article: supplementary data 1 supplementary data 2 appendix a supplementary data to this article can be found online at https://doi org/10 1016/j euros2022 12 015 ."

"

 Financial disclosures: Neil J. Shah certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Neil J. Shah has a consulting/advisory role with Merck Sharp & Dohme LLC, Exelixis, Aravive and has received research funding from Aravive. Sneha Sura is an employee of Ontada. Reshma Shinde is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and own stock in Merck & Co., Inc., Rahway, NJ, USA. Junxin Shi is an employee of Ontada. Puneet Singhal is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and own stock in Merck & Co., Inc., Rahway, NJ, USA. Nicholas J. Robert is an employee of and owns stock in Ontada; has a consulting/advisory role with New Century Health, Bristol-Myers Squibb, Boehringer Ingelheim, and Advi; and has received honoraria from Roche and Bristol-Myers Squibb. Nicholas J. Vogelzang has a consulting/advisory role with Pfizer, Bayer, Genentech/Roche, AstraZeneca, Caris Life Sciences, Tolero Pharmaceuticals, Merck, Astellas Pharma, Boehringer Ingelheim, Corvus Pharmaceuticals, Modra Pharmaceuticals, Clovis Oncology, Janssen Oncology, Eisai, and Myovant Sciences; participates in speaker bureaus for Bayer, Sanofi, Genentech/Roche, Bristol-Myers Squibb, Seattle Genetics/Astellas, Clovis Oncology, AVEO, Myovant Sciences, and AstraZeneca; has received travel and accommodation expenses from Genentech/Roche, US Oncology, Pfizer, Bayer/Onyx, Exelixis, AstraZeneca/MedImmune, and Sanofi/Aventis; has provided expert testimony for Novartis; holds stock and other ownership interests in Caris Life Sciences; has received honoraria from Pfizer, Novartis, and Merck; and has received research funding from US Oncology, Endocyte, Merck, and Suzhou Kintor Pharmaceuticals. Rodolfo F. Perini is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and own stock in Merck & Co., Inc., Rahway, NJ, USA. Robert J. Motzer has a consulting/advisory role for Novartis, Eisai, Exelixis, Merck, Genentech/Roche, Incyte, Lilly, Pfizer, AstraZeneca, EMD Serono, and Calithera Biosciences; has received travel and accommodation expenses from Bristol-Myers Squibb; and has received research funding from Pfizer, Bristol-Myers Squibb, Eisai, Novartis, Genentech/Roche, Exelixis, and Merck. Financial disclosures:"

"

Financial disclosures: Neil J. Shah certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Neil J. Shah has a consulting/advisory role with Merck Sharp & Dohme LLC, Exelixis, Aravive and has received research funding from Aravive. Sneha Sura is an employee of Ontada. Reshma Shinde is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and own stock in Merck & Co., Inc., Rahway, NJ, USA. Junxin Shi is an employee of Ontada. Puneet Singhal is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and own stock in Merck & Co., Inc., Rahway, NJ, USA. Nicholas J. Robert is an employee of and owns stock in Ontada; has a consulting/advisory role with New Century Health, Bristol-Myers Squibb, Boehringer Ingelheim, and Advi; and has received honoraria from Roche and Bristol-Myers Squibb. Nicholas J. Vogelzang has a consulting/advisory role with Pfizer, Bayer, Genentech/Roche, AstraZeneca, Caris Life Sciences, Tolero Pharmaceuticals, Merck, Astellas Pharma, Boehringer Ingelheim, Corvus Pharmaceuticals, Modra Pharmaceuticals, Clovis Oncology, Janssen Oncology, Eisai, and Myovant Sciences; participates in speaker bureaus for Bayer, Sanofi, Genentech/Roche, Bristol-Myers Squibb, Seattle Genetics/Astellas, Clovis Oncology, AVEO, Myovant Sciences, and AstraZeneca; has received travel and accommodation expenses from Genentech/Roche, US Oncology, Pfizer, Bayer/Onyx, Exelixis, AstraZeneca/MedImmune, and Sanofi/Aventis; has provided expert testimony for Novartis; holds stock and other ownership interests in Caris Life Sciences; has received honoraria from Pfizer, Novartis, and Merck; and has received research funding from US Oncology, Endocyte, Merck, and Suzhou Kintor Pharmaceuticals. Rodolfo F. Perini is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and own stock in Merck & Co., Inc., Rahway, NJ, USA. Robert J. Motzer has a consulting/advisory role for Novartis, Eisai, Exelixis, Merck, Genentech/Roche, Incyte, Lilly, Pfizer, AstraZeneca, EMD Serono, and Calithera Biosciences; has received travel and accommodation expenses from Bristol-Myers Squibb; and has received research funding from Pfizer, Bristol-Myers Squibb, Eisai, Novartis, Genentech/Roche, Exelixis, and Merck. 

Funding/Support and role of the sponsor: This work is supported by Merck & Co., Inc., Rahway, NJ, United States of America. The sponsor played a role in the design and conduct of the study; analysis and interpretation of the data; and preparation, review, and approval of the manuscript."